Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Bergamo, Italy.
Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Bergamo, Italy.
Kidney Int. 2020 Nov;98(5):1084-1087. doi: 10.1016/j.kint.2020.06.026.
Gain-of-function variants in CFB encoding factor B (FB), a component of the alternative pathway C3 convertase, have been reported in a minority of patients with aHUS and result in massive C3 activation. Zhang et al. describe the functional characterization of a novel FB variant (p.Ser367Arg) that they identified in 2 unrelated aHUS pedigrees who had undetectable C3 levels. The mutant FB caused strong C3 cleavage in fluid-phase but also C3 deposition on cell surface. This commentary addresses the implications of these findings for understanding the complexity of complement-related genetic renal diseases.
在补体替代途径 C3 转化酶的组成部分 CFB 编码因子 B (FB) 中,已有少数 aHUS 患者存在功能获得性变异,导致大量 C3 激活。Zhang 等人描述了他们在 2 个无关联的 aHUS 家系中发现的一种新型 FB 变异体 (p.Ser367Arg) 的功能特征,这些家系的 C3 水平检测不到。该突变 FB 在液相中引起强烈的 C3 切割,也导致 C3 在细胞表面沉积。这篇评论讨论了这些发现对理解补体相关遗传性肾脏疾病复杂性的影响。